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ABSTRACT 
Magnetic Resonance Imaging or Contrast-Enhanced Computed Tomography of the 
Liver as Standard Workup Before Treatment for Rectal Cancer 
Mathias Utterberg, Degree Project in Medicine, 2018 
Department of Surgery, Sahlgrenska Academy, University of Gothenburg, Sweden 
Supervisor: Eva Haglind 
Introduction: The liver is the most commonly affected site regarding rectal cancer 
metastasis. The Swedish national cancer care guidelines recommend a routine of a 
preoperative contrast-enhanced computed tomography (CT) to examine the liver for 
metastases before rectal cancer treatment. The NU Hospital Group (NU) conforms to the 
national guidelines. The Sahlgrenska University Hospital (SU) differs by conducting 
magnetic resonance imaging (MRI) of the liver.  
Objective: To compare the efficiency of MRI with contrast-enhanced CT as the index 
examination of the liver in patients with newly diagnosed rectal cancer.  
Methods: Clinical data regarding 320 patients with rectal cancer (160 from SU and 160 from 
NU) were collected from the Regional ColoRectal Cancer Register, 2013–2015. Information 
regarding such as liver examinations and surgery was collected from hospital records. All 
index liver examinations that did not confirm or rule out liver metastasis were considered 
“inconclusive” and subsequently re-evaluated by two radiologists.  
Results: 274 patients were analyzed. 13 % in the MRI group and 15 % in the CT group 
underwent supplementary liver examinations before treatment for rectal cancer (p = 0.635). 
Within 18 months after the index examination, a total of 17 % of patients were diagnosed 
with liver metastases in both groups combined (p = 0.765), and 8 % of patients in the MRI 
group versus 2 % in the CT group were treated with liver surgery (p = 0.016). 
Conclusions: MRI did not show any clinical advantage over contrast-enhanced CT as the 
index examination of the liver among patients with newly diagnosed rectal cancer. Thus, this 
study gives no reason to change the current Swedish national guidelines for rectal cancer. 
Key words: Magnetic resonance imaging, computed tomography, rectal cancer, liver 
metastasis 
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INTRODUCTION 
Between 2005 and 2015, there was a 33 percent rise in the number of patients who were 
diagnosed with cancer worldwide. A large proportion of this increase in incidence was due to 
population growth and ageing, and the incidence is expected to rise further (1). During the 
same period, there was also a 17 percent worldwide increase in the total number of cancer-
related deaths (2). In 2015, 16 percent of all deaths were caused by cancer, which made it the 
second leading cause of death globally after cardiovascular disease (2).  
 
In the view of the increased incidence, every step of cancer diagnosis and treatment should be 
evaluated regarding its outcomes. Therefore, this study is aimed to evaluate a part of the 
radiological workup before treatment for rectal cancer.  
 
Rectal Cancer 
Rectal cancer implies cancerous tumors in the most distal 15 cm of the large intestines (the 
rectum) and is often defined in combination with colon cancer as colorectal cancer.  
 
Epidemiology 
In 2015, colorectal cancer was the third most common type of cancer worldwide in both sexes 
combined, after breast cancer and tracheal/bronchus/lung cancer (1). According to the 2011 
statistics from the Swedish National Board of Health and Welfare, rectal cancer accounted for 
approximately one-third of all cases of colorectal cancer and was by itself the ninth most 
common type of cancer in Sweden (3). In 2011, the Swedish rectal cancer incidences among 
men and women were 24.6 and 17.3 cases per 100 000 persons respectively, affecting nearly 
2 000 individuals. The same year, the total number of Swedish individuals with rectal cancer 
 5 
(the prevalence) was 15 846 (3). On average, only five percent of patients are diagnosed 
before 50 years of age, which makes rectal cancer a rarer disease in younger populations (4). 
 
Risk factors 
The average lifetime risk of getting colorectal cancer in western populations range 3–5 
percent (5), and there are several risk factors to consider. According to a report from the 
American Institute for Cancer Research, men are at higher risk of getting colorectal cancer 
than women (6). The report further states that increased body weight, consumption of red or 
processed meat, prolonged heavy smoking, and alcohol intake correlate to increased risks of 
colorectal cancer (6). On the other hand, intake of vitamin D and calcium could decrease the 
risk, as could the consumption of milk, possibly also yoghurt, and other foods such as whole 
grains, poultry, and fish (6, 7).  
 
Though the majority of colorectal cancers appear sporadically, some are genetically 
conditioned. About 15–20 percent of patients with colorectal cancer have colorectal cancers 
in their family histories, and another 5–10 percent even suffer from hereditary colorectal 
cancer syndromes (5). Having a first-degree relative diagnosed with colorectal cancer at 50–
70 years of age nearly doubles the average lifetime risk of being diagnosed with colorectal 
cancer. Having an even younger first-degree relative with colorectal cancer nearly triples the 
risk (5).  
 
Finally, apart from environmental factors and hereditary conditions, other diseases could also 
affect the risk of getting colorectal cancer. Both type 2 diabetes mellitus and inflammatory 
bowel diseases, particularly prolonged and widespread ulcerative colitis, seem to increase the 
risk of developing colorectal cancer (5).  
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Pathophysiology 
All factors that increase the risk of colorectal cancer do so by affecting the cells and tissues of 
the large intestines in one way or another. Over the years, gene mutations and epigenetic 
alterations will accumulate in colorectal epithelial cells. As a result, cytological abnormalities 
or neoplasms, such as adenomas, can begin to form (5). It is widely accepted that colorectal 
cancer typically emerges from an early adenoma that evolves into a more advanced adenoma 
before finally becoming a malignant tumor. However, the proportion of adenomas that turn 
malignant and the time this transition takes are difficult to study and still subjects of 
discussion. In a follow-up study of polyps ≥ 1.0 cm in diameter, the cumulative risk of 
malignancy at the site of the index polyp after 5, 10, and 20 years was 2.5 percent, 8 percent, 
and 24 percent respectively (8).  
 
Diagnosis and the Swedish national cancer care guidelines for rectal cancer 
Rectal bleeding, more frequent defecation, diarrhea, incomplete evacuation of stool , mucous 
in stool, form changes in stools, constipation, and pain are potential symptoms of rectal 
cancer (4, 9). A combination of these symptoms provides high predictive values for rectal 
cancer and should lead to further clinical assessments (4).  
 
The current Swedish national cancer care guidelines for rectal cancer were implemented in 
2016 to limit the differences in how patients with a suspected or confirmed rectal cancer are 
treated between regions and hospitals in Sweden (4). According to these guidelines, 
presenting at least one of the following symptoms should result in an immediate referral for a 
colonoscopy: changes in otherwise stable bowel habits for >4 weeks without any apparent 
explanation in patients older than 40 years of age, clinical imaging findings indicating rectal 
cancer, rectal palpation or endoscopy findings indicating rectal cancer, visual blood in stools 
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in high-risk patients, visual blood in stools, even though rectal palpation or endoscopy is 
unable to locate an apparent bleeding source, and/or anemia that cannot be explained by 
standard anemia assessments. If the colonoscopy is inconclusive, a computed tomographic 
colonography may provide additional information for a more accurate diagnosis (4).  
 
After confirming the presence of rectal cancer, the current Swedish national guidelines 
recommend a routine preoperative radiological examination of the pelvic region using 
magnetic resonance imaging and of the thorax/abdomen using contrast-enhanced computed 
tomography for prognosis estimations and an accurate clinical cancer staging (4). The staging 
conforms to the Union for International Cancer Control (UICC) TNM Classification of 
Malignant Tumors (T – the extent of invasion and size of the primary tumor, N – the absence 
or presence of regional lymph node metastases, M – the absence or presence of distant 
metastases; the addition of numbers to these three components indicates the extent of the 
malignant disease). The TNM classification can be further translated into stages I–IV, where 
IV accounts for the most advanced cancer stages (10).  
 
Treatment 
With all the necessary diagnostic information at hand, colorectal surgeons (if needed, also 
liver and/or thoracic surgeons), oncologists, radiologists, pathologists, and contact nurses, 
gather in multidisciplinary team conferences (MDT) to discuss and, if no additional 
examinations are needed, subsequently make decisions regarding the best possible treatments 
for each patient. Over the past years, these conferences have become very important for the 
multimodal management and treatment of patients with rectal cancer (and other types of 
cancer) (4). Treatment initiations should follow as soon as possible after treatment decisions 
are made. As a matter of fact, according to the current Swedish national guidelines, the time 
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between the date of rectal cancer diagnosis and treatment initiation should not exceed 42 days 
(4).  
 
The standard treatment for rectal cancer is resection surgery (4). Some patients, depending on 
their cancer stage, will receive neoadjuvant (preoperative) radio- or radiochemotherapy to 
down-stage the cancer before surgery. Doing so may limit the risks for persistent 
micrometastases (microscopic lesions spatially separated from the gross tumor) and local 
recurrences at the site of the index tumor after excision, thus improving the long-term 
outcome (4). 
 
For rectal cancers that are staged according to the TNM classification as T1, T2, T3, and 
sometimes even T4 after neoadjuvant radio- or radiochemotherapy, a total mesorectal 
excision is currently the standard surgical technique (5). It is performed by excising the 
rectum while concurrently and in one piece completely removing the rectal mesentery, 
including all local mesenteric lymph nodes (5). 
 
There are currently three different rectal excision procedures to consider for radical resection 
of the primary rectal tumor. Firstly, there is anterior resection, meaning that the rectum is 
removed, and an anastomosis is formed. At the same time, a loop-ileostomy is often formed to 
temporarily protect the anastomosis during the initial period after surgery (4). The “covering 
ileostomy” can be expected to reduce the clinical consequences if anastomotic dehiscence 
would occur (11). A recent study reported that an early closure of the ileostomy could further 
reduce the risk for complications (12). Secondly, if sphincter preservation is not possible, an 
abdominoperineal excision is currently the preferred procedure. It involves removal of the 
anus and sometimes also parts of the pelvic floor. Because the anus is removed, a permanent 
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colostomy is created (4). Finally, there is Hartmann’s procedure, which is recommended for 
patients with sphincter dysfunction and/or high morbidity. This procedure is largely 
equivalent to the anterior resection but differs by resulting in a permanent colostomy rather 
than an anastomosis (4). In carefully selected cases, most often among fragile and elderly 
patients, local excision of the rectal tumor, such as a transendoscopic excision, can be used as 
an alternative to resection surgery (4).  
 
If a patient presents urgent symptoms that are caused by an obstructive rectal tumor, 
emergency surgery may be performed to relieve the obstruction. One method is forming a 
defunctioning stoma without resection of the primary tumor (4). As an alternative in selected 
patients with a more proximal rectal cancer, colonic stenting could be used to avoid 
emergency surgery (13, 14). A stent or defunctioning stoma can also be used as symptom 
relief in palliative settings (4). 
 
Prognosis 
According to the Swedish National Board of Health and Welfare, the prognosis for rectal 
cancer has improved over the last decades due to enhanced diagnostic methods and 
oncological treatments (3). The Swedish overall 10-year relative survival has increased by 
approximately 20 percent since the 1980s. In 2011, the overall relative 5-year/10-year 
survival rates after rectal cancer among Swedish men and women were 62.9/53.9 percent and 
64.2/58.0 percent respectively (3). 
 
Although the overall survival has improved, rectal cancer treatments are still frequently 
associated with serious complications, such as anastomotic leakage, toxicity after 
chemotherapy, pelvic floor dysfunction, fecal incontinence, erectile dysfunction, and 
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dyspareunia (5). Moreover, spreading of rectal cancer (metastasis) to other locations in the 
body can cause additional symptoms and require other treatments that also could affect the 
prognosis and the quality of life (5). Therefore, information regarding possible metastasis is 
important to acquire at an early stage of the disease before treatment decisions are made at 
multidisciplinary team conferences (4).  
 
Rectal Cancer Liver Metastasis 
The liver is the most commonly affected site regarding rectal cancer metastasis (15). 
Although there is currently no actual consensus on how to exactly categorize rectal cancer 
metastasis with respect to when in time it is diagnosed, metastasis that is detected within six 
months after the rectal cancer diagnosis could be defined as synchronous. Metastasis that is 
detected at a later stage could be defined as metachronous (15). Approximately 14–20 percent 
of all patients with rectal cancer are diagnosed with synchronous liver metastasis, and up to 
30 percent of patients are likely to eventually develop liver metastasis within five years after 
rectal cancer diagnosis (16, 17).  
 
Treatment 
Depending on whether a patient suffers from synchronous or metachronous rectal cancer 
metastasis and whether the metastases are liver-limited or systemic, different treatment 
pathways are available. Patients with synchronous liver metastasis do often require complex 
and synchronized management of both the rectal tumor and the metastasis (15). Contrastingly, 
patients who have undergone curative resection of the primary rectal tumor before they are 
diagnosed with metachronous liver metastasis can receive metastasis-focused treatments (15). 
If the rectal cancer metastasis is systemic, chemotherapy is currently the main treatment (15).  
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There are currently three different strategies to surgically remove synchronous rectal cancer 
liver metastases. The “classic approach” comprises a primary resection of the rectal tumor, 
followed by adjuvant chemotherapy and subsequent liver resection. The “liver-first approach” 
implies that the liver metastases are removed before the rectal resection. The third available 
strategy is simultaneous liver and rectal resection (18, 19). The choice of method is debatable. 
The rationale for the classic approach is that the rectal tumor is usually the main cause of 
symptoms and subsequent metastasis, suggesting that the primary rectal tumor should be 
removed first (18, 19). Contrastingly, some studies suggest that liver metastasis is the likeliest 
course of subsequent systemic metastases, thus supporting liver surgery as the first operative 
intervention (18, 19). The synchronous approach has the advantage of removing the 
macroscopic cancer burden in one session. However, although simultaneous surgery may 
reduce the total blood loss and shorten the total time of hospitalization, a combination of 
complex liver and bowel surgery is more likely to result in considerable morbidity (18, 19).  
 
The amount of liver parenchyma that can be safely resected depends on different factors, such 
as age and comorbidity. In healthy adult individuals, up to 80 percent of the liver can be 
resected (20). Patients with chemotherapy-induced liver injuries require a residual liver 
volume of approximately 30 percent, and patients with liver cirrhosis require at least 40 
percent (20). Before surgery, neoadjuvant chemotherapy could shrink the metastases to 
increase the chances for a complete and curative resection while also limiting the amount of 
liver parenchyma that has to be resected as well as reducing the number of intrahepatic 
micrometastases (21). 
 
Non-resectional ablative treatments are also available for the treatment of liver metastases. 
Ablative treatments use energy sources for heating up the metastases to induce coagulative 
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oncosis (15). The most commonly used ablative treatments utilize radio frequencies 
(radiofrequency ablation) or microwave energy and can be used as alternatives to surgery or 
in adjunction to it (15, 22). However, because of various technical circumstances, ablative 
treatments are not efficient enough for treatment of all cases of liver metastasis (23). 
 
Prognosis 
Rectal cancer mortality is predominantly determined by liver metastasis (24). Numerous 
factors, including the location, size, number, and level of differentiation of the metastases as 
well as N-status and primary tumor resection status, are related to the patient survival rates 
(24). The overall 5-year survival rate for patients with colorectal cancer and synchronous liver 
metastasis is poor without treatment but can reach up to at least 46 percent if the metastases 
are surgically removed (15, 25).  
 
Radiological Assessment of the Liver 
According to the current Swedish national guidelines, adequate preoperative cross-sectional 
imaging of the liver is recommended to examine possible liver metastasis in patients with 
rectal cancer before any treatment decisions are made. For this purpose, the guidelines 
specifically recommend a contrast-enhanced computed tomography (CT). If a patient, for 
some reason, cannot be adequately examined using a contrast-enhanced CT of the liver, liver 
metastasis can also be evaluated using magnetic resonance imaging (MRI), contrast-enhanced 
ultrasonography, or a combination of positron emission tomography and CT (PET-CT) (4). 
However, PET-CT is rarely used to primarily examine liver metastasis. 
 
 13 
Computed tomography 
CT is a non-invasive procedure that use ionizing x-ray photons to produce cross-sectional 
images of the body. Because internal structures of similar densities sometimes can be difficult 
to distinguish, contrast agents are often added to many CT protocols to enhance different 
tissues and fluids on the resulting images (26, 27). The current Swedish national guidelines 
recommend the usage of an intravenously administered low-osmolar contrast medium when 
examining the liver for rectal cancer metastasis (4). A non-contrast enhanced CT can only in 
some cases confirm liver metastasis; however, metastatic disease cannot be ruled out in the 
absence of intravenous contrast agents. 
 
Magnetic resonance imaging 
Similar to CT, MRI is a non-invasive procedure that can be used to visualize internal 
structures. An MRI utilizes a strong magnetic field and radiofrequency waves that interact 
with tissues to produce images of the body in varying shades of grey. During the examination, 
the magnetic field aligns hydrogen nuclei that normally are randomly distributed within 
tissues. Radiofrequency pulses excite the aligned hydrogen nuclei, which in turn, depending 
on tissue characteristics, relax into their original state of thermal equilibrium while emitting 
new radiofrequency pulses that can be measured, calculated, and presented as cross-sectional 
images. Using a compilation of different radiofrequency pulses, sequences, and contrast 
agents, information from molecules in the body, particularly from soft tissues, are translated 
into highly detailed images (28).  
  
An MRI protocol is composed of a set of different sequences to display tissues and 
pathological processes as adequately as possible. When examining the liver regarding rectal 
cancer metastasis, the current Swedish national guidelines recommend that an MRI includes 
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T1-, T2-, and diffusion-weighted sequences as well as T1-weighted sequences enhanced with 
intravenous (preferably liver-specific) gadolinium contrast agents (4). T1-weighted images 
present the longitudinal relaxation of the hydrogen nuclei. T2-weighted images present the 
corresponding transversal relaxation. As results, fluids show up darker on T1-weighted 
images and contrastingly brighter on T2-weighted images (28). The addition of gadolinium 
contrast agents to the T1-weighted sequences shortens the T1-relaxation. Intravenously 
administered gadolinium contrast agents will, therefore, facilitate the imaging of blood 
vessels. Apart from the regular extracellular gadolinium contrast agents, there are also liver-
specific gadolinium agents that can be absorbed by hepatocytes to enhance the imaging of the 
liver (28). Finally, diffusion-weighted imaging detects the random movements and free 
diffusion of water molecules both intra- and extracellularly as well as across cell membranes. 
In highly cellular tissues, such as tumors, the apparent diffusion of water is often impeded, 
which shows up on diffusion-weighted images (28).  
 
Magnetic resonance imaging or computed tomography as a preoperative liver examination 
According to a randomized controlled trial comparing preoperative contrast-enhanced  
CT with diffusion-weighted MRI of the liver in patients with rectal cancer, the per-patient 
sensitivity/specificity was 50/100 percent for contrast-enhanced CT and up to 100/100 percent 
for diffusion-weighted MRI. Furthermore, the per-lesion sensitivity was 17 percent for 
contrast-enhanced CT and 89 percent for diffusion-weighted MRI (25). The proposition that 
MRI has superior diagnostic accuracy for liver metastases compared with contrast-enhanced 
CT is further supported in larger meta-analyses and another randomized controlled trial (29-
31). Additionally, potential cost-effectiveness is associated with MRI as a replacement for 
contrast-enhanced CT, according to an Australian study comparing the incremental costs 
relative to the incremental benefits of contrast-enhanced CT and MRI for diagnosis of liver 
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metastasis in patients with colorectal cancer (32). Still, the current Swedish national 
guidelines recommend, as mentioned, a contrast-enhanced CT as the routine preoperative 
examination of the liver before making treatment decisions at multidisciplinary team 
conferences regarding patients who are newly diagnosed with rectal cancer (4). 
 
Based on the fact that other studies have shown a higher sensitivity/specificity for MRI 
compared with contrast-enhanced CT regarding liver metastases, the Sahlgrenska University 
Hospital has implemented a routine that generally deviates from the current Swedish national 
guidelines. Rather than examining the pelvic organs with an MRI and the liver with a 
contrast-enhanced CT, the Sahlgrenska University Hospital use a routine of an adapted and 
combined MRI protocol of the pelvic region and the upper abdomen (including the liver) (33). 
The added liver examination is a condensed liver MRI protocol focusing on diffusion-
weighted imaging. The intention is to provide a more accurate rectal cancer staging with 
fewer supplementary liver examinations during the primary workup before treatment for 
rectal cancer. Thereby, the aim is to shorten the time between diagnosis and treatment 
initiations. However, no studies have been performed to substantiate this hypothesis.  
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SPECIFIC OBJECTIVES 
The purpose of this study was to compare the efficacy of MRI with contrast-enhanced CT as 
the index examination of the liver in patients with a newly diagnosed rectal cancer. 
 
Hypothesis 
Our hypothesis is that, compared with contrast-enhanced CT, MRI as the index examination 
of the liver results in a reduced need of supplementary liver examinations before treatment for 
rectal cancer. Furthermore, we hypothesize that MRI as the index examination of the liver 
results in a larger proportion of patients who are diagnosed with liver metastases and also in a 
larger proportion of patients who undergo liver surgery within 18 months after the index liver 
examination. 
 
Primary Objective 
To compare MRI with contrast-enhanced CT as the index examination of the liver regarding 
the proportion of patients who underwent supplementary radiological liver examinations 
before treatment for rectal cancer. 
 
Secondary Objectives 
To compare MRI with contrast-enhanced CT as the index examination of the liver regarding:  
1. the proportion of patients who were diagnosed with liver metastases, and 
2. the proportion of patients who were treated with liver resection and/or ablation for 
liver metastases within 18 months after the index examination of the liver.  
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MATERIALS AND METHODS 
Study Design 
This was a retrospective study using clinical data from patients who were diagnosed with 
rectal cancer at the Sahlgrenska University Hospital and within the NU Hospital Group in the 
Region Västra Götaland, Sweden.  
 
The inclusion criteria were patients with a rectal cancer diagnosis, C20.9 (ICD-10), that was 
registered at the Sahlgrenska University Hospital or within the NU Hospital Group before 
2015-12-31. The exclusion criteria included missing or inadequate routine preoperative MRI 
or contrast-enhanced CT of the liver and local rectal tumor excisions. 
 
Study population 
Assuming that the proportions of patients who underwent supplementary radiological liver 
examinations before the treatment for rectal cancer were 15 percent after an index contrast-
enhanced CT and 5 percent after an index MRI, a two-sided t-test at 5 percent level with 80 
percent power requires a sample size of 138 evaluable patients in each group (n = 276). This 
estimation was based on clinical experience. 
 
The Swedish Rectal Cancer Register was established in 1995 for registration of data on rectal 
cancers in Sweden. All Swedish hospitals report to the register (34). The ColoRectal Cancer 
Register combines data from both patients with colon cancers and patients with rectal cancer. 
 
Lists of patients were assembled by working backwards through the Regional ColoRectal 
Cancer Register from 2015-12-31 until 320 patients with rectal cancer were included (160 
patients from the Sahlgrenska University Hospital and 160 patients from the NU Hospital 
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Group). Hence, cohorts of patients who were diagnosed with rectal cancer between 2014-12-
08–2015-12-31 and 2013-12-06–2015-12-31 at the Sahlgrenska University Hospital and the 
NU Hospital Group respectively were generated. Each patient was then assigned a specific 
study ID before the study population was divided into two groups depending on which 
radiological method that had been used for the index examination of the liver (MRI or 
contrast-enhanced CT), regardless of at what hospital the patients had been treated.  
 
Data Collection 
Data were collected from three different sources: [1] the Regional ColoRectal Cancer 
Register, [2] hospital records, including radiology reports, and [3] re-evaluations of selected 
index liver examinations as part of this study. 
 
Data concerning age, gender, body mass index, hospital affiliation, time for rectal cancer 
diagnosis, time for oncological treatments, type of oncological treatments, clinical TNM 
stage, and American Association of Anesthesiologists classification were retrieved from the 
Regional ColoRectal Cancer Register.  
 
All relevant data between the time for the index liver examination and 2017-12-31 were 
collected from hospital records and radiology reports using a customized case report form. 
Such data included dates for index and supplementary liver examinations and outcomes 
regarding liver metastasis, dates for multidisciplinary team conferences (MDT), and dates and 
the Nordic Medico-Statistical Committee (NOMESCO) codes for any conducted liver 
surgery. Radiology reports were categorized as either conclusive or inconclusive depending 
on whether liver metastasis had been confirmed/ruled out (conclusive), or neither 
(inconclusive). 
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As part of this study, all index liver examinations that resulted in inconclusive radiology 
reports regarding liver metastasis were re-evaluated by two radiologists (P. Kälebo and P. 
Nilsson). Jointly, they assessed the examinations regarding liver metastasis and registered 
their findings in the database. However, the re-evaluations did not affect the outcomes of this 
study but were included to possibly provide a deeper understanding of the results. These re-
evaluations were performed three to four years after the writing of the original radiology 
reports and did in no way affect the clinical management of the patients.  
 
Because the date for the first treatment decision at a multidisciplinary conference would have 
been the final step in the workup before rectal cancer treatment, it might have been an 
interesting variable to consider. However, these dates were difficult to collect and therefore 
not part of this study.  
 
Statistical Methods 
Data processing 
The first liver examination (MRI or contrast-enhanced CT) that was used to examine the liver 
regarding rectal cancer metastasis before treatment was defined as the index liver 
examination. If a patient had undergone supplementary radiological examinations, which 
resulted in radiology reports indicating that the liver had been evaluated regarding rectal 
cancer metastasis, these examinations were sorted into two categories:  
1. “Liver examinations”, including MRI, contrast-enhanced CT, contrast-enhanced 
ultrasonography; and 
2. “Other examinations”, including other evaluable examinations of the liver, such as CT 
colonography.  
Only supplementary examinations of the first group were analyzed in this study. 
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Further data processing was conducted as follows: [1] Synchronous liver metastasis was 
defined as radiologically confirmed liver metastasis within six months after the date of rectal 
cancer diagnosis. Liver metastasis that was detected more than six months after diagnosis was 
defined as metachronous. [2] The clinical TNM stages of the rectal cancers were translated 
into stages I–IV based on the Union for International Cancer Control (UICC) TNM 
classification of malignant tumors (10). [3] Patients who did not undergo rectal resection 
surgery, who were treated with stents or stomas alone, or who received oncological treatments 
in palliative settings were considered as given palliative treatment. [4] The date for treatment 
initiation was derived from the first date of neoadjuvant treatments and rectal/liver surgery. 
Regarding the palliative patients who did not receive any of these treatments, the dates for 
treatment initiations were derived from the date of the multidisciplinary team conference 
(MDT) at which the first treatment decision was likely to have been made.  
 
Only data from within 18 months after the index liver examination were analyzed. The 
timeframe of 18 months was chosen in order for this study to also include the 12-month 
follow-up radiological liver examination even when some of the included patients had 
undergone longer neoadjuvant treatments before surgery. 
 
Variable analysis 
Two different index examinations of the liver were compared: [1] MRI and [2] contrast-
enhanced CT. The primary outcome involved a comparison regarding the proportion of 
patients who underwent supplementary liver examinations after the index examination of the 
liver before treatment for rectal cancer. The comparison also involved two secondary 
outcomes: [1] the proportion of patients who were diagnosed with liver metastases, and [2] 
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the proportion of patients who were treated with liver resection or ablation within 18 months 
after the index liver examination.  
 
IBM SPSS 24.0 was used for statistical calculations. An alpha level of 0.05 was used, and 
differences resulting in p-values of less than 0.05 were considered statistically significant. The 
demographic analysis was performed using Student’s t-test or Mann-Whitney U-test for 
continuous variables and Pearson’s chi-squared test or Fisher’s exact test for categorical 
variables. The primary and secondary outcomes were analyzed using Pearson’s chi-squared 
test. 
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ETHICAL ASPECTS 
Patients were not contacted, and only already registered information was included in this 
study. Data of this kind are considered to have a small impact on personal integrity, and the 
cohort size was such that tracing any of the results to an individual patient is not possible. 
Thus, in accordance with the Declaration of Helsinki Ethical Principles for Medical Research 
Involving Human Subjects (35), the requirement of informed consent was waived. Once the 
data collection was completed, the database was anonymized by the removal of all personal 
identification numbers.  
 
This project received approval by the Regional Ethical Review Board in Gothenburg (Dnr: 
352-17) and was registered at clinicaltrials.gov (NCT03463616).  
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RESULTS 
After examining the lists of the 320 patients included from the Regional ColoRectal Cancer 
Register, 46 patients were excluded from the analyses (Figure 1).  
39 patients fulfilled at least one of the exclusion criteria: 5 patients did not have rectal cancer, 
21 patients had not undergone an adequate routine preoperative MRI or contrast-enhanced CT 
of the liver, and 13 patients had undergone local excisions of rectal tumors. Furthermore, 7 
non-evaluable patients were identified: 4 cases were doublets of already included patients and 
3 patients were missing essential register information. The remaining 274 patients were 
subdivided into two groups with respect to whether MRI or contrast-enhanced CT was used as 
the index examination of the liver (122 patients with index MRI, 152 patients with index 
contrast-enhanced CT). Demographics and baseline patient features are presented in Table 1. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Notes: 
MRI, Magnetic Resonance Imaging; CE-CT, Contrast-Enhanced Computed Tomography 
Sahlgrenska University Hospital 
N = 160 
NU Hospital Group 
N = 160 
Exclusions 
Doublets: 4 
No rectal cancer: 5 
No preoperative MRI/CE-CT: 21 
Local excisions: 13  
Missing information: 3 
MRI 
N = 122 
CE-CT 
N = 152 
Final study population 
N = 274 
Figure 1. Flow chart of the study population. Some patients fulfilled more than one 
exclusion criterion. 
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The two groups were similar with respect to gender, body mass index, American Society of 
Anesthesiologists classification, days from diagnosis to treatment, the reception of 
neoadjuvant treatment, and therapeutic approach (curative or palliative) (Table 1). All patients 
were discussed at multidisciplinary team conferences (MDT). Statistically significant 
differences were discovered regarding age at diagnosis, hospital affiliation, and clinical tumor 
stage.  
 
Table 1. Demographics of 274 patients with rectal cancer. 
 
Characteristics MRIᵃ (N = 122) CE-CT  ᵇ(N = 152) Total (N = 274)
Male — no. (%) 81 (66) 90 (59) 171 (62)
Age at diagnosis* — yr (mean±SD) 67±13 71±10 69±12
          Range (min–max) 25–92 30–93 25–93
Body Mass Index — kg/m² (mean±SD) 25±4 26±4 26±4
          Range (min–max) 18–34 17–36 17–36
          Missing data — no. (%) 21 (17) 42 (28) 63 (23)
Hospital** — no.  (%)
          Sahlgrenska University Hospital 121 (99) 18 (12) 139 (51)
          NU Hospital Group 1 (1) 134 (88) 135 (49)
Clinical UICC stage** — no. (%)
          Stage I 31 (25) 9 (6) 40 (15)
          Stage II 36 (30) 21 (14) 57 (21)
          Stage III 29 (24) 86 (56) 115 (42)
          Stage IV 19 (15) 30 (20) 49 (18)
          Missing data 7 (6) 6 (4) 13 (4)
American Society of Anesthesiologists classification — no. (%)
          I: Healthy 15 (12) 17 (11) 32 (12)
          II: Mild systemic disease 68 (55) 68 (45) 136 (50)
          III: Severe systemic disease 19 (16) 25 (16) 44 (16)
          IV: Severe life-threatening systemic disease 1 (1) 3 (2) 4 (1)
          Missing data 19 (16) 39 (26) 58 (21)
Multidiciplinary team conference — no. (%)
          Yes 122 (100) 152 (100) 274 (100)
Days from diagnosis to treatment initiationᵃ
          Median no. (IQR) 54 (42–75) 56 (44–70) 56 (43–70)
Neoadjuvant treatment — no. (%)
          Yes 66 (54) 87 (57) 153 (56)
          No 42 (34) 58 (38) 100 (36)
          Missing data 14 (12) 7 (5) 21 (8)
Therapeutic approach† — no. (%)
          Curative 100 (82) 108 (71) 208 (76)
          Palliative 19 (16) 37 (24) 56 (20)
          Missing data 3 (2) 7 (5) 10 (4)
ᵃMagnetic resonance imaging
ᵇContrast-enhanced computed tomography
†Treatment initiations represent the start of neoadjuvant treatment or surgery, or, if missing, the first treatment decision at MDT. 
*Student's t-test / **Pearson’s chi-squared test resulted in a two-sided p-value < 0.05.
Type of index liver examination
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 In the MRI group, 12 percent of the patients were diagnosed with liver metastasis at the index 
examination of the liver, compared with 9 percent of the patients in the contrast-enhanced CT 
group. Furthermore, compared with MRI, contrast-enhanced CT as the index examination of 
the liver resulted in an almost four times larger proportion of inconclusive radiology reports 
regarding liver metastasis (Table 2). 
 
The proportions of patients who underwent supplementary liver examinations (MRI, contrast-
enhanced CT, or contrast-enhanced ultrasonography) before treatment were 13 percent in the 
MRI group and 15 percent in the contrast-enhanced CT group. In both groups, these patients 
underwent a median number of one supplementary liver examination. Altogether, 21 and 32 
extra liver examinations were performed on patients the MRI and contrast-enhanced CT 
groups respectively (Table 3). 
Table 2. Radiology report results from index liver examinations regarding liver metastasis.  
 
 MRIᵃ (N = 122) CE-CT  ᵇ(N = 152) Total (N = 274)
Results 0.011
          Liver metastasis 14 (12) 14 (9) 28 (10)
          No liver metastasis 103 (84) 115 (76) 218 (80)
          Inconclusive 5 (4) 23 (15) 28 (10)
ᵃMagnetic resonance imaging
ᵇContrast-enhanced computed tomography
Index liver examinations — no. (%)
Type of index liver examination P-value
Table 3. Patients who underwent supplementary liver examinations before treatment for rectal cancer.  
 
MRIᵃ (N = 122) CE-CT  ᵇ(N = 152) Total (N = 274)
Total no. of patients who underwent 
supplementary liver examinations 16 (13) 23 (15) 39 (14) 0.635
No. of supplementary liver examinations 0.652
0 106 (87) 129 (85) 235 (86)
1 14 (11) 17 (11) 31 (10)
2 1 (1) 4 (2) 5 (1)
3 0 1 (1) 1 (1)
4 0 1 (1) 1 (1)
5 1 (1) 0 1 (1)
†Treatment initiation represent the start of neoadjuvant treatment or surgery, or, if missing, the first treatment decision at MDT. 
ᵃMagnetic resonance imaging
ᵇContrast-enhanced computed tomography
Type of index liver examinationSupplementary liver examinations 
before treatment initiation† — no. (%)
P-value
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Contrast-enhanced CT resulted in a significantly larger proportion of patients with 
inconclusive radiology reports from index examinations of the liver compared with MRI, but 
a large number of these patients never underwent any supplementary liver examinations 
before treatment for rectal cancer (Table 4).  
 
All 28 inconclusive radiology reports from index examinations were re-evaluated by two 
radiologists as part of this study. These re-evaluations resulted in 2 index MRI and 13 index 
contrast-enhanced CT examinations that were still reported as inconclusive regarding liver 
metastasis. In real life, out of these individuals with consistently inconclusive index 
examinations of the liver, 1 out of 2 patients in the MRI group and 6 out of 13 patients in the 
contrast-enhanced CT group underwent supplementary liver examinations before treatment 
for rectal cancer.  
 
The proportion of patients who developed liver metastases from rectal cancer within 18 
months after the index liver examination was 16 percent in the MRI group and 18 percent in 
the contrast-enhanced CT group. Altogether, 40 patients developed synchronous liver 
Table 5. Patients who developed liver metastases within 18 months after the index examination. 
 
Liver metastasis — no. (%) MRIᵃ (N = 122) CE-CT  ᵇ(N = 152) Total (N = 274)
Metastasis 1.000
          Synchronous 17 (14) 23 (15) 40 (15)
          Metachronous 3 (3) 4 (3) 7 (3)
          Total 20 (16) 27 (18) 47 (17) 0.765
ᵃMagnetic resonance imaging
ᵇContrast-enhanced computed tomography
Liver metastasis — no. (%) MRIᵃ (N = 122) CE-CT  ᵇ(N = 152) Total (N = 274)
Total 20 (16) 27 (18) 47 (17) 0.765
          Synchronous 17 (85) 23 (85) 40 (85)
          Metachronous 3 (15) 4 (15) 7 (15)
ᵃMagnetic resonance imaging
ᵇContrast-enhanced computed tomography
Type of index liver examination P-value
Type of index liver examination P-value
Table 4. Patients with inconclusive radiology reports from index examinations and the proportion of those who 
underwent supplementary examinations before treatment for rectal cancer. 
 
Inconclusive index examinations — no. (%) MRIᵃ (N = 122) CE-CT  ᵇ(N = 152) Total (N = 274)
Total 5 (4) 23 (15) 28 (10) 0.003
          Resulting in supplementary examinations 2 (40) 10 (44) 12 (43)
ᵃMagnetic resonance imaging
ᵇContrast-enhanced computed tomography
Ta ej med…:
Study re-evaluation† — no. of patients (%)
          Inconclusive results changed to conclusive 3 10 13 0.639
          Inconclusive that remained inconclusive 2 13 15
          …that resulted in supplementary xaminations1 6 7 1.000
Type of index liver examination P-value
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metastases and 7 patients developed metachronous liver metastases. The difference in 
incidences of liver metastasis between the two groups was not statistically significant (Table 
5).   
 
Surgery was more commonly performed on patients in the MRI group. 88 percent of the 
patients in the index MRI group and 76 percent of patients in the contrast-enhanced CT group 
underwent rectal and/or liver surgery within 18 months from the index liver examination. In 
the MRI group, rectal surgery was performed on 87 percent of the patients, compared with 75 
percent in the contrast-enhanced CT group. In both groups, anterior resection (including 
Hartmann’s procedure) was the most commonly performed procedure for rectal surgery. An 
almost four times larger proportion of patients in the MRI group compared with the contrast-
enhanced CT group underwent liver surgery within 18 months after the index examination 
(Table 6).  
Table 6. Patients who were treated with surgery. 
 
Surgery† — no. (%) MRIᵃ (N = 122) CE-CT  ᵇ(N = 152) Total (N = 274)
Any surgery 0.011
          Yes 107 (88) 115 (76) 222 (81)
          No 15 (12) 37 (24) 52 (19)
Rectal surgery 0.014
          Yes 106 (87) 114 (75) 220 (80)
               Anterior resection, incl. Hartmann's procedure 56 (53) 66 (58) 122 (55)
               Abdominoperineal excision 39 (37) 48 (42) 87 (40)
               Other 11 (10) 0 11 (5)
Liver surgery 0.016
          Yes 10 (8) 3 (2) 13 (5)
               Resection 5 (50) 1 (33) 6 (46)
               Ablation 1 (10) 1 (33) 2 (15)
               Both 4 (40) 1 (34) 5 (39)
†Within 18 months from the index liver examination.
ᵃMagnetic resonance imaging
ᵇContrast-enhanced computed tomography. 
Type of index liver examination P-value
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DISCUSSION 
Whether an MRI or a contrast-enhanced CT was used for the index examination of the liver 
among patients with newly diagnosed rectal cancer, there were no significant differences in 
the proportions of patients who underwent supplementary liver examinations before treatment 
for rectal cancer or were diagnosed with liver metastases throughout this study. Liver surgery 
was more often performed on the patients in the MRI group. 
 
Other studies have advocated a higher sensitivity and specificity for MRI regarding the 
diagnosis of liver metastasis (25, 29-31). It was, therefore, not surprising that contrast-
enhanced CT appeared to result in a larger proportion of inconclusive radiology reports. 
Consequently, it seemed reasonable that a larger proportion of the patients who underwent an 
index contrast-enhanced CT should have been subjected to supplementary liver examinations 
to either confirm or rule out concurrent liver metastasis before treatment for rectal cancer. 
One possible reason as to why this rationale did not apply in this study could be that some 
radiologists may have preferred to give inconclusive radiology reports in case there was the 
slightest doubt regarding possible liver metastasis. If so, it seems likely that these 
examinations were re-evaluated at multidisciplinary team conferences, which, despite the 
original radiology report, may have resulted in liver metastasis being either confirmed or 
ruled out. Subsequently, there would have been no further need for additional liver 
examinations before initiating rectal cancer treatments, even though the original radiology 
report suggested otherwise. 
 
Demographics were expected to differ significantly regarding the patients’ hospital 
affiliations, since the Sahlgrenska University Hospital used routine MRI for the index 
examination of the liver in patients with newly diagnosed rectal cancer, whereas the NU 
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Hospital Group used routine contrast-enhanced CT for the same purpose. This implies that the 
majority of the patients in the MRI group were managed at the Sahlgrenska University 
Hospital and that the majority of the patients in the contrast-enhanced CT group were 
managed within the NU Hospital Group. However, demographics further suggested that the 
patients who were examined using an index contrast-enhanced CT were both older and 
initially diagnosed with more advanced rectal cancers.  
 
People living in metropolitan areas may have easier access to hospitals than patients in rural 
areas. Because the Sahlgrenska University Hospital had a catchment area that consisted of a 
larger metropolitan area, whereas the catchment area for the NU Hospital Group consisted of 
more rural areas of the Region Västra Götaland, Sweden, patients who were managed at the 
Sahlgrenska University Hospital might have sought health care at an earlier stage of their 
disease. It is, therefore, possible that the differences in age and cancer stage between the 
groups resulted from a longer patients’ delay among the patients who were managed within 
the NU Hospital Group due to differences in the accessibility of healthcare. Moreover, these 
differences in demographics could partially explain why patients in the contrast-enhanced CT 
group were less treated with liver surgery than patients in the MRI group, even though there 
was no difference in the incidence of liver metastasis between the two groups.  
 
Another possible explanation to why liver surgery was more often performed on patients in 
the MRI group is based on the fact that all liver surgery within the Region Västra Götaland 
was carried out at the Sahlgrenska University Hospital. The better accessibility to liver 
surgeons may, therefore, have made it easier for patients who were primarily managed at the 
Sahlgrenska University Hospital to receive a referral for liver surgery compared with patients 
who were primarily managed within the NU Hospital Group. In conclusion, not only was 
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hospital affiliation associated with the method used for the index examination of the liver, but 
it was also likely a confounding factor.  
 
There are no previous studies to compare these results with. This study provides a good 
foundation to base future research on. 
 
Strengths and Limitations 
One strength was that all patients who had been diagnosed with rectal cancer at the 
Sahlgrenska University Hospital or within the NU Hospital Group during a specific period 
were included in this study unless they met any of the exclusion criteria. Further strengths 
were that there was no patient selection, basic clinical data were gathered from a register with 
high validity, and all patient records were accessible. The case report form was designed 
before initiating any data collections from hospital records. The actual retrieval of data was 
performed by one person (M. Utterberg).  
 
One limitation was the retrospective design. Further limitations were that the power 
estimation was based on clinical experience and that the patient cohorts may have differed, in 
some respects, based on hospital affiliation. Furthermore, additional MRI, contrast-enhanced 
CT, or contrast-enhanced ultrasonography that were used primarily to visualize other 
pathological processes occurring with rectal cancer might sometimes also have resulted in 
statements regarding liver metastasis. Therefore, the total number of liver examinations may 
have been slightly exaggerated in both groups.  
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Conclusions 
The usage of MRI for the index examination of the liver among patients with newly 
diagnosed rectal cancer did not show any clinical advantage over contrast-enhanced CT. 
Thus, this study gives no reason to change the current Swedish national guidelines regarding 
the recommendation of a contrast-enhanced CT of the liver as standard workup before 
treatment for rectal cancer. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Magnetkamera eller skiktröntgen av levern vid utredning av ändtarmscancer? 
Examensarbete 30 HP, läkarprogrammet 
Av Mathias Utterberg 
Handledare: Eva Haglind 
Avdelningen för kirurgi, Sahlgrenska Akademin, Göteborg 2018 
 
I takt med att vi människor blir både fler och äldre beräknas antalet cancerfall världen över att 
öka, enligt en studie från Världshälsoorganisationen (WHO). I dagsläget drabbar 
ändtarmscancer årligen ungefär 2 000 svenskar och är den nionde vanligaste cancerformen i 
Sverige. Symtomen är till stor del ospecifika, men drabbade patienter talar ofta om förändrade 
avföringsvanor, ofrivillig viktnedgång och ibland även blödningar från ändtarmen.  
 
Sedan 2016 finns det nationella riktlinjer för en förbestämd och strukturerad vårdprocess för 
att vid både misstänkt och konstaterad ändtarmscancer begränsa skillnaderna i hur patienter 
utreds och behandlas mellan alla Sveriges sjukhus. Eftersom levern är det organ som oftast 
drabbas vid spridning (metastasering) av ändtarmscancer rekommenderas att dessa patienter 
bland annat genomgår en skiktröntgenundersökning av levern. Då metastasering kan påverka 
både prognos och behandlingsmetod är det viktigt att veta om en patient har levermetastaser 
eller inte innan behandling påbörjas. 
 
Inom NU-sjukvården i norra delarna av Västra Götalandsregionen undersöks patienter med 
ändtarmscancer enligt de nationella riktlinjerna. En del tidigare studier har dock visat att 
magnetkamera kan vara bättre än skiktröntgen på att upptäcka levermetastaser. Därför avviker 
Sahlgrenska Universitetssjukhuset i Göteborg från de nationella riktlinjerna och erbjuder 
istället sina patienter en magnetkameraundersökning av levern. Denna avvikelse syftar till att 
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minska andelen patienter som behöver genomgå extra leverundersökningar innan ett 
behandlingsbeslut kan fattas och på så vis också förkorta tiden mellan diagnos och 
behandlingsstart. Därmed har denna studie haft för avsikt att jämföra magnetkamera och 
skiktröntgen vid den första leverundersökningen bland patienter med nydiagnostiserad 
ändtarmscancer.  
 
Totalt analyserades 274 patienter som diagnosticerats med ändtarmscancer vid Sahlgrenska 
Universitetssjukhuset eller inom NU-sjukvården. Oavsett om magnetkamera eller 
skiktröntgen använts för att initialt undersöka levern var det ingen skillnad i andelen patienter 
som behövde genomgå extra leverundersökningar innan behandling kunde påbörjas. Det var 
heller ingen skillnad i andelen patienter som under studiens gång diagnostiserats med 
levermetastaser. Däremot var det vanligare med leverkirurgi bland patienterna som initialt 
undersökts med magnetkamera.  
 
Majoriteten av de patienter som initialt genomgått en magnetkameraundersökning av levern 
hade diagnosticerats med ändtarmscancer vid Sahlgrenska Universitetssjukhuset, medan 
större delen av de patienter som genomgått en skiktröntgen hade diagnosticerats inom NU-
sjukvården. Därför är det möjligt att patienternas sjukhustillhörighet kan ha påverkat studiens 
resultat. För det första finns alla regionens leverkirurger vid Sahlgrenska Sjukhuset, vilket kan 
ha påverkat tillgången på leverkirurgi. För det andra noterades att de patienter som genomgått 
skiktröntgen, och alltså i stor utsträckning hanterats inom NU-sjukvården, var både äldre och 
oftare hade en mer avancerad ändtarmscancer. Detta skulle kunna bero på att tillgången på 
vård kan vara mer begränsad på landsbygden än i storstäderna och att patienterna som 
undersökts med skiktröntgen därmed sökt vård i ett senare skede än de som undersökts med 
magnetkamera. Svårare cancerstadier och därmed försämrade prognoser bland patienterna i 
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gruppen som undersökts med skiktröntgen kan ha lett till att de i större utsträckning fått avstå 
från leverkirurgi.  
 
Sammanfattningsvis kunde inte denna studie påvisa några kliniska fördelar med att välja 
magnetkamera över skiktröntgen i samband med den initiala leverundersökningen vid 
nydiagnostiserad ändtarmscancer. Alltså finns i dagsläget ingen anledning att revidera de idag 
rådande riktlinjerna i detta avseende. 
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